TAFI phenomenon and its clinical significance
https://doi.org/10.30629/0023-2149-2023-101-11-521-524
Abstract
Thrombin activatable fi brinolysis inhibitor (TAFI) is one of the key proteins of fi brinolysis and infl ammation systems. Based on literature data, information is presented on the biological eff ects of TAFI, the mechanisms of its activation, gene polymorphism that determines the duration of its action and activity. Nosological forms are listed, where TAFI is important in the pathogenesis of the development of diseases, its role in experimental and laboratory studies, and the possibility of pharmacological infl uence on the activity of this protein.
About the Authors
I. N. Bokarev
Russian Association on Thrombosis, Hemostasis and Vascular Pathology A. Schmidt–B. Kudryashov
Russian Federation
Russian Federation
Bokarev Igor N.
129327, Moscow
A. P. Melnikov
Moscow Regional Research Institute of Obstetrics and Gynecology; Russian Association on Thrombosis, Hemostasis and Vascular Pathology A. Schmidt–B. Kudryashov
Russian Federation
Russian Federation
Melnikov Andrey P.
101000, Moscow
129327, Moscow
S. I. Burykh
Moscow Regional Research Institute of Obstetrics and Gynecology
Russian Federation
Russian Federation
Burykh Sofia I.
101000, Moscow
References
1. Bokarev I.N., Popova L.V., Savin A.A. DIC-syndrom and Constant Intravascular Microcoagulation of blood. Moscow. 2016. (In Russian).
2. Fedorenko V.A., Melnikov A.P. Fibrinolysis disorders in obstetric and gynecological practice. Russian Bulletin of an obstetrician-gynecologist.2022;22(6):18–26. (In Russian). DOI: 10.17116/rosakush20222206118
3. Nesheim M., Bajzar L. The discovery of TAFI. J. Thromb. Haemostasis. 2005;3(10):2139–2146. DOI: 10.1111/j.1538-7836.2005.01280.x
4. Kwaan H.C. The role of fi brinolytic system in health and disease. Int. J. Mol. Sci. 2022;23(9):5262. DOI: 10.3390/ijms23095262
5. Urano T., Castellino F.J., Suzuki Y. Regulation of plasminogen activation on cell surfaces and fi brin. J. Thromb. Haemost. 2018;16(8):1487–1497. DOI:10.1111/jth.14157
6. Marta-Enguita J., Navarro-Oviedo M., Muñoz R. et al. Inside the thrombus: association of hemostatic parameters with outcomes in large vessel stroke patients. Front. Neurol. 2021;12:599498. DOI:10.3389/fneur.2021.599498
7. Bridge K., Revill C., Macrae F. et al. Inhibition of plasmin-mediated TAFI activation may aff ect development but not progression of abdominal aortic aneurysms. PLoS One. 2017;12(5):e0177117. DOI: 10.1371/journal.pone.0177117
8. Okada M., Tominaga N., Honda G., Nishioka J., Akita N., Hayashi T., Suzuki K., Moriuchi H. A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation. Blood Adv. 2020;4(12):2631–2639. DOI: 10.1182/bloodadvances.2019001155
9. Wyseure T., Cooke E.J., Declerck P.J. et al. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. Blood. 2018;132(15):1593–1603. DOI: 10.1182/blood-2018-01-8284349001155
10. Colucci M., Incampo F., Cannavò A. et al. Reduced fi brinolytic resistance in patients with factor XI defi ciency. Evidence of a thrombinindependent impairment of the thrombin-activatable fi brinolysis inhibitor pathway. J. Thromb. Haemost. 2016;14(8):1603–1614. DOI: 10.1111/jth.13342
11. Totoki T., Ito T., Kakuuchi M., Yashima N., Maruyama I., Kakihana Y. An evaluation of circulating activated TAFI in septic DIC: a case series and review of the literature. Thromb. J. 2022;20(1):6.
12. Vollrath J.T., Marzi I., Herminghaus A., Lustenberger T., Relja B. Post-traumatic sepsis is associated with increased c5a and decreased TAFI levels. J. Clin. Med. 2020;9(4)1230. DOI: 10.3390/jcm9041230
13. Bazzi Z.A., Lanoue D., El-Youssef M. et al. Activated thrombinactivatable fi brinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. BMC Cancer. 2016;16:328. DOI: 10.1186/s12885-016-2359-1
14. Radovanović-Dinić B., Tešić-Rajković S., Ignjatovic A., Grgov S. Thrombin activatable fi brinolysis inhibitor as an indicator of the severity of acute pancreatitis. Turkish J. Gastroenterol. 2018;29(4):488–493: DOI: 10.5152/tjg.2018.17666
15. Gumus I.I., Kargili A., Karakurt F. et al. Levels of thrombin activatable fi brinolysis inhibitor in gestational diabetes mellitus. Gynecol. Endocrinol. 2013;29(4):327–330: DOI: 10.3109/09513590.2010.501884
16. Fang P., Cai D., Du L., Shen F., Zhang C., Li M. Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion. Clin. Appl. Thromb. 2021;27. DOI: 10.1177/10760296211029720
17. Acosta-Tejeda M., Baptista-González H., Rosenfeld-Mann F., Trueba-Gómez R., García-Latorre E. Association between genotype and plasma levels of thrombin-activated fi brinolysis inhibitor (TAFI) in the development of preeclampsia. Thromb. Res. 2011;128(4):e39– 42. DOI: 10.1016/j.thromres.2011.05.019
18. ЕlDanasori N., Abulata N., Shaheen I.A., ElGendy A.M., ElKhayat W. Thrombin-activatable fi brinolysis inhibitor gene polymorphism (TAFI1040C/T) in women with recurrent spontaneous abortion. Clin. Appl. Thromb. 2018;24(3):532–535. DOI: 10.1177/1076029617695485
19. Gorar S., Alioglu B., Ademoglu E. et al. Is there a tendency for thrombosis in gestational diabetes mellitus? J. Lab. Physicians. 2016;8(2):101–105. DOI: 10.4103/0974-2727.180790
20. Godtfredsen A.C.M., Sidelmann J.J., Gram J.B., Andersen M., GlintborgD. Fibrin lysability is associated with central obesity and infl ammation in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 2020;99(8):1078–1084. DOI: 10.1111/aogs.13825
21. Karakurt F., Gumus II., Bavbek N. et al. Increased thrombin-activatable fi brinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol. Endocrinol. 2008;24(9):491– 497. DOI: 10.1080/09513590802291824
22. Zorio E., Gilabert-Estelles J., Espana F., Ramon L., Cosin R., Es tel les A. Fibrinolysis: the key to new pathogenetic mecha nisms. Curr. Med. Chem. 2008;15(9):923–929. DOI: 10.2174/092986708783955455
23. Bentov Y., Brown T.J., Akbari M.R. et al. Polymorphic variation of genes in the fi brinolytic system and the risk of ovarian cancer. PLoS One. 2009;4(6):e5918. DOI: 10.1371/journal.pone.0005918
24. Cai Y., Jin H., Cao LQ., Gao Q., Tao J. Overexpression of TAFI promotes epithelial mesenchymal transition in endometriosis. Eur. Rev. Med. Pharmacol. Sci. 2017;21(24):5527–5533. DOI: 10.26355/EURREV_201712_13988
25. Neil E.K., Stewart R.J., Schneider M.M., Nesheim M.E. A functional assay for measuring activated thrombin-activatable fi brinolysis inhibitor in plasma. Anal. Biochem. 2004,330;332–341. DOI: 10.1016/j.ab.2004.04.007
26.
Review
For citations:
Bokarev I.N., Melnikov A.P., Burykh S.I. TAFI phenomenon and its clinical significance. Clinical Medicine (Russian Journal). 2023;101(11):521-524. (In Russ.) https://doi.org/10.30629/0023-2149-2023-101-11-521-524
Views:
886
Email this article 